Cargando…

Sex differences in congestive markers in patients hospitalized for acute heart failure

AIMS: We sought to examine sex differences in congestion in patients hospitalized for acute heart failure (AHF). Understanding congestive patterns in women and men with AHF may provide insights into sex differences in the presentation and prognosis of AHF patients. METHODS AND RESULTS: In a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espersen, Caroline, Campbell, Ross T., Claggett, Brian, Lewis, Eldrin F., Groarke, John D., Docherty, Kieran F., Lee, Matthew M.Y., Lindner, Moritz, Biering‐Sørensen, Tor, Solomon, Scott D., McMurray, John J.V., Platz, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120385/ https://www.ncbi.nlm.nih.gov/pubmed/33709520 http://dx.doi.org/10.1002/ehf2.13300

Ejemplares similares

Body mass index and B‐lines on lung ultrasonography in chronic and acute heart failure
por: Brainin, Philip, et al.
Publicado: (2020)

Within trial comparison of survival time projections from short‐term follow‐up with long‐term follow‐up findings
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Left atrial inflow propagation velocity derived by color M-mode Doppler in acute heart failure
por: Johannessen, Øyvind, et al.
Publicado: (2022)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Association between lung ultrasound findings and invasive exercise haemodynamics in patients with undifferentiated dyspnoea
por: Platz, Elke, et al.
Publicado: (2018)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Insights into foundational therapies for heart failure with reduced ejection fraction
por: McMurray, John J. V., et al.
Publicado: (2022)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Talking to patients with heart failure about end of life
por: Campbell, Ross T., et al.
Publicado: (2018)

Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
por: Sabe, Marwa A., et al.
Publicado: (2016)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
por: Docherty, Kieran F., et al.
Publicado: (2020)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life
por: Vu, Katja, et al.
Publicado: (2021)

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
por: Chatur, Safia, et al.
Publicado: (2023)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes
por: Wolsk, Emil, et al.
Publicado: (2022)

Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI
por: Wang, Xiaowen, et al.
Publicado: (2023)

Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction
por: Docherty, Kieran F., et al.
Publicado: (2021)

Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
por: Wolsk, Emil, et al.
Publicado: (2017)

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
por: Packer, Milton, et al.
Publicado: (2021)

Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial
por: Wijkman, Magnus O., et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration
por: Seferovic, Jelena P., et al.
Publicado: (2018)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
por: Cannon, Jane A, et al.
Publicado: (2015)

Postsystolic Shortening by Speckle Tracking Echocardiography Is an Independent Predictor of Cardiovascular Events and Mortality in the General Population
por: Brainin, Philip, et al.
Publicado: (2018)

Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?
por: Modin, Daniel, et al.
Publicado: (2018)

Congestive Nephropathy
por: D’ Marco, Luis
Publicado: (2022)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study
por: Modin, Daniel, et al.
Publicado: (2022)

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4domgou5r75hg6339g4n3bspek